336 results on '"Sonneveld, E."'
Search Results
2. The KMT2A recombinome of acute leukemias in 2023
- Author
-
Meyer, C., Larghero, P., Almeida Lopes, B., Burmeister, T., Gröger, D., Sutton, R., Venn, N. C., Cazzaniga, G., Corral Abascal, L., Tsaur, G., Fechina, L., Emerenciano, M., Pombo-de-Oliveira, M. S., Lund-Aho, T., Lundán, T., Montonen, M., Juvonen, V., Zuna, J., Trka, J., Ballerini, P., Lapillonne, H., Van der Velden, V. H. J., Sonneveld, E., Delabesse, E., de Matos, R. R. C., Silva, M. L. M., Bomken, S., Katsibardi, K., Keernik, M., Grardel, N., Mason, J., Price, R., Kim, J., Eckert, C., Lo Nigro, L., Bueno, C., Menendez, P., zur Stadt, U., Gameiro, P., Sedék, L., Szczepański, T., Bidet, A., Marcu, V., Shichrur, K., Izraeli, S., Madsen, H. O., Schäfer, B. W., Kubetzko, S., Kim, R., Clappier, E., Trautmann, H., Brüggemann, M., Archer, P., Hancock, J., Alten, J., Möricke, A., Stanulla, M., Lentes, J., Bergmann, A. K., Strehl, S., Köhrer, S., Nebral, K., Dworzak, M. N., Haas, O. A., Arfeuille, C., Caye-Eude, A., Cavé, H., and Marschalek, R.
- Published
- 2023
- Full Text
- View/download PDF
3. How do novel and conventional agri-food wastes, co-products and by-products improve soil functions and soil quality?
- Author
-
Gebremikael, M.T., Ranasinghe, A., Hosseini, P.S., Laboan, B., Sonneveld, E., Pipan, M., Oni, F.E., Montemurro, F., Höfte, M., Sleutel, S., and De Neve, S.
- Published
- 2020
- Full Text
- View/download PDF
4. Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels
- Author
-
Sedek, L, Flores-Montero, J, van der Sluijs, A, Kulis, J, Marvelde, J, Philippe, J, Bottcher, S, Bitter, M, Caetano, J, van der Velden, V, Sonneveld, E, Buracchi, C, Santos, A, Lima, M, Szczepanski, T, van Dongen, J, Orfao, A, Sedek L., Flores-Montero J., van der Sluijs A., Kulis J., Marvelde J. T., Philippe J., Bottcher S., Bitter M., Caetano J., van der Velden V. H. J., Sonneveld E., Buracchi C., Santos A. H., Lima M., Szczepanski T., van Dongen J. J. M., Orfao A., Sedek, L, Flores-Montero, J, van der Sluijs, A, Kulis, J, Marvelde, J, Philippe, J, Bottcher, S, Bitter, M, Caetano, J, van der Velden, V, Sonneveld, E, Buracchi, C, Santos, A, Lima, M, Szczepanski, T, van Dongen, J, Orfao, A, Sedek L., Flores-Montero J., van der Sluijs A., Kulis J., Marvelde J. T., Philippe J., Bottcher S., Bitter M., Caetano J., van der Velden V. H. J., Sonneveld E., Buracchi C., Santos A. H., Lima M., Szczepanski T., van Dongen J. J. M., and Orfao A.
- Abstract
Objective interpretation of FC results may still be hampered by limited technical stan-dardization. The EuroFlow consortium conducted a series of experiments to determine the impact of different variables on the relative distribution and the median fluorescence intensity (MFI) of markers stained on different cell populations, from both healthy donors and patients’ samples with distinct hematological malignancies. The use of different anticoagulants; the time interval between sample collection, preparation, and acquisition; pH of washing buffers; and the use of cell surface membrane-only (SM) vs. cell surface plus intracytoplasmic (SM+CY) staining protocols, were evaluated. Our results showed that only monocytes were represented at higher percentages in EDTA-vs. heparin-anticoagulated samples. Application of SM or SM+CY protocols resulted in slight differences in the percentage of neutrophils and debris determined only with particular antibody combinations. In turn, storage of samples for 24 h at RT was associated with greater percentage of debris and cell doublets when the plasma cell disorder panel was used. Furthermore, 24 h storage of stained cells at RT was selectively detrimental for MFI levels of CD19 and CD45 on mature B-and T-cells (but not on leukemic blasts, clonal B-and plasma cells, neutrophils, and NK cells). The obtained results showed that the variables evaluated might need to be tailored for sample and cell type(s) as well as to the specific markers compared; however, defining of well-balanced boundaries for storage time, staining-to-acquisition delay, and pH of washing buffer would be a valid recommendation for most applications and circumstances described herein.
- Published
- 2022
5. Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse
- Author
-
Antic, Z, Yu, J, Bornhauser, B, Lelieveld, S, van der Ham, C, van Reijmersdal, S, Morgado, L, Elitzur, S, Bourquin, J, Cazzaniga, G, Eckert, C, Camos, M, Sutton, R, Cave, H, Moorman, A, Sonneveld, E, Geurts van Kessel, A, van Leeuwen, F, Hoogerbrugge, P, Waanders, E, Kuiper, R, Antic Z., Yu J., Bornhauser B. C., Lelieveld S. H., van der Ham C. G., van Reijmersdal S. V., Morgado L., Elitzur S., Bourquin J. -P., Cazzaniga G., Eckert C., Camos M., Sutton R., Cave H., Moorman A. V., Sonneveld E., Geurts van Kessel A., van Leeuwen F. N., Hoogerbrugge P. M., Waanders E., Kuiper R. P., Antic, Z, Yu, J, Bornhauser, B, Lelieveld, S, van der Ham, C, van Reijmersdal, S, Morgado, L, Elitzur, S, Bourquin, J, Cazzaniga, G, Eckert, C, Camos, M, Sutton, R, Cave, H, Moorman, A, Sonneveld, E, Geurts van Kessel, A, van Leeuwen, F, Hoogerbrugge, P, Waanders, E, Kuiper, R, Antic Z., Yu J., Bornhauser B. C., Lelieveld S. H., van der Ham C. G., van Reijmersdal S. V., Morgado L., Elitzur S., Bourquin J. -P., Cazzaniga G., Eckert C., Camos M., Sutton R., Cave H., Moorman A. V., Sonneveld E., Geurts van Kessel A., van Leeuwen F. N., Hoogerbrugge P. M., Waanders E., and Kuiper R. P.
- Abstract
Introduction: One-quarter of the relapses in children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occur very early (within 18 months, before completion of treatment), and prognosis in these patients is worse compared to cases that relapse after treatment has ended. Methods: In this study, we performed a genomic analysis of diagnosis–relapse pairs of 12 children who relapsed very early, followed by a deep-sequencing validation of all identified mutations. In addition, we included one case with a good initial treatment response and on-treatment relapse at the end of upfront therapy. Results: We observed a dynamic clonal evolution in all cases, with relapse almost exclusively originating from a subclone at diagnosis. We identified several driver mutations that may have influenced the outgrowth of a minor clone at diagnosis to become the major clone at relapse. For example, a minimal residual disease (MRD)-based standard-risk patient with ETV6-RUNX1-positive leukemia developed a relapse from a TP53-mutated subclone after loss of the wildtype allele. Furthermore, two patients with TCF3-PBX1-positive leukemia that developed a very early relapse carried E1099K WHSC1 mutations at diagnosis, a hotspot mutation that was recurrently encountered in other very early TCF3-PBX1-positive leukemia relapses as well. In addition to alterations in known relapse drivers, we found two cases with truncating mutations in the cohesin gene RAD21. Conclusion: Comprehensive genomic characterization of diagnosis–relapse pairs shows that very early relapses in BCP-ALL frequently arise from minor subclones at diagnosis. A detailed understanding of the therapeutic pressure driving these events may aid the development of improved therapies.
- Published
- 2022
6. A novel germline PAX5 single exon deletion in a pediatric patient with precursor B-cell leukemia.
- Author
-
Engelen, N. van, Roest, M., Dijk, F. van, Sonneveld, E., Bladergroen, R., Reijmersdal, S.V. van, Velden, V.H. van der, Hoogeveen, P.G., Kors, W.A., Waanders, E., Jongmans, M.C.J., Kuiper, R.P, Engelen, N. van, Roest, M., Dijk, F. van, Sonneveld, E., Bladergroen, R., Reijmersdal, S.V. van, Velden, V.H. van der, Hoogeveen, P.G., Kors, W.A., Waanders, E., Jongmans, M.C.J., and Kuiper, R.P
- Abstract
01 september 2023, Item does not contain fulltext
- Published
- 2023
7. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement
- Author
-
Bomken, S, Enshaei, A, Schwalbe, E, Mikulasova, A, Dai, Y, Zaka, M, Fung, K, Bashton, M, Lim, H, Jones, L, Karataraki, N, Winterman, E, Ashby, C, Attarbaschi, A, Bertrand, Y, Bradtke, J, Buldini, B, Burke, G, Cazzaniga, G, Gohring, G, De Groot-Kruseman, H, Haferlach, C, Nigro, L, Parihar, M, Plesa, A, Seaford, E, Sonneveld, E, Strehl, S, Van der Velden, V, Rand, V, Hunger, S, Harrison, C, Bacon, C, Van Delft, F, Loh, M, Moppett, J, Vormoor, J, Walker, B, Moorman, A, Russell, L, Bomken, Simon, Enshaei, Amir, Schwalbe, Edward C, Mikulasova, Aneta, Dai, Yunfeng, Zaka, Masood, Fung, Kent Tm, Bashton, Matthew, Lim, Huezin, Jones, Lisa, Karataraki, Nefeli, Winterman, Emily, Ashby, Cody, Attarbaschi, Andishe, Bertrand, Yves, Bradtke, Jutta, Buldini, Barbara, Burke, G. A. Amos, Cazzaniga, Giovanni, Gohring, Gudrun, De Groot-Kruseman, Hesta A, Haferlach, Claudia, Nigro, Luca Lo, Parihar, Mayur, Plesa, Adriana, Seaford, Emma, Sonneveld, Edwin, Strehl, Sabine, Van der Velden, Vincent Hj, Rand, Vikki, Hunger, Stephen P, Harrison, Christine J, Bacon, Chris M, Van Delft, Frederik W, Loh, Mignon L, Moppett, John, Vormoor, Josef, Walker, Brian A, Moorman, Anthony V, Russell, Lisa J, Bomken, S, Enshaei, A, Schwalbe, E, Mikulasova, A, Dai, Y, Zaka, M, Fung, K, Bashton, M, Lim, H, Jones, L, Karataraki, N, Winterman, E, Ashby, C, Attarbaschi, A, Bertrand, Y, Bradtke, J, Buldini, B, Burke, G, Cazzaniga, G, Gohring, G, De Groot-Kruseman, H, Haferlach, C, Nigro, L, Parihar, M, Plesa, A, Seaford, E, Sonneveld, E, Strehl, S, Van der Velden, V, Rand, V, Hunger, S, Harrison, C, Bacon, C, Van Delft, F, Loh, M, Moppett, J, Vormoor, J, Walker, B, Moorman, A, Russell, L, Bomken, Simon, Enshaei, Amir, Schwalbe, Edward C, Mikulasova, Aneta, Dai, Yunfeng, Zaka, Masood, Fung, Kent Tm, Bashton, Matthew, Lim, Huezin, Jones, Lisa, Karataraki, Nefeli, Winterman, Emily, Ashby, Cody, Attarbaschi, Andishe, Bertrand, Yves, Bradtke, Jutta, Buldini, Barbara, Burke, G. A. Amos, Cazzaniga, Giovanni, Gohring, Gudrun, De Groot-Kruseman, Hesta A, Haferlach, Claudia, Nigro, Luca Lo, Parihar, Mayur, Plesa, Adriana, Seaford, Emma, Sonneveld, Edwin, Strehl, Sabine, Van der Velden, Vincent Hj, Rand, Vikki, Hunger, Stephen P, Harrison, Christine J, Bacon, Chris M, Van Delft, Frederik W, Loh, Mignon L, Moppett, John, Vormoor, Josef, Walker, Brian A, Moorman, Anthony V, and Russell, Lisa J
- Abstract
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukemia (BCP-ALL) carries an immunoglobulin-MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukemia and use of individualized treatment schedules of unproven efficacy. Here we compare the molecular characteristics of these conditions and investigate historic clinical outcome data. We identified 90 cases registered in a national BCP-ALL clinical trial/registry. When present, diagnostic material underwent cytogenetic, exome, methylome and transcriptome analyses. The outcomes analyzed were 3-year event-free survival and overall survival. IG-MYC-r was identified in diverse cytogenetic backgrounds, co-existing with either established BCP-ALL-specific abnormalities (high hyperdiploidy, n=3; KMT2A-rearrangement, n=6; iAMP21, n=1; BCR-ABL1, n=1); BCL2/BCL6-rearrangements (n=15); or, most commonly, as the only defining feature (n=64). Within this final group, precursor-like V(D)J breakpoints predominated (8/9) and KRAS mutations were common (5/11). DNA methylation identified a cluster of V(D)J-rearranged cases, clearly distinct from Burkitt leukemia/lymphoma. Children with IG-MYC-r within that subgroup had a 3-year event-free survival of 47% and overall survival of 60%, representing a high-risk BCP-ALL. To develop effective management strategies this group of patients must be allowed access to contemporary, minimal residual disease-adapted, prospective clinical trial protocols.
- Published
- 2023
8. The KMT2A recombinome of acute leukemias in 2023
- Author
-
Meyer, C, Larghero, P, Almeida Lopes, B; https://orcid.org/0000-0003-1072-470X, Burmeister, T; https://orcid.org/0000-0003-4843-2876, Gröger, D, Sutton, R; https://orcid.org/0000-0002-0188-6005, Venn, N C, Cazzaniga, G, Corral Abascal, L, Tsaur, G, Fechina, L, Emerenciano, M; https://orcid.org/0000-0003-2337-8420, Pombo-de-Oliveira, M S; https://orcid.org/0000-0002-1507-004X, Lund-Aho, T, Lundán, T, Montonen, M, Juvonen, V, Zuna, J; https://orcid.org/0000-0002-0887-3709, Trka, J, Ballerini, P, Lapillonne, H, Van der Velden, V H J; https://orcid.org/0000-0001-9457-3763, Sonneveld, E, Delabesse, E, de Matos, R R C; https://orcid.org/0000-0002-8737-1669, Silva, M L M; https://orcid.org/0000-0003-2549-1320, Bomken, S; https://orcid.org/0000-0001-9163-5738, Katsibardi, K, Keernik, M, Schäfer, Beat W; https://orcid.org/0000-0001-5988-2915, et al, Meyer, C, Larghero, P, Almeida Lopes, B; https://orcid.org/0000-0003-1072-470X, Burmeister, T; https://orcid.org/0000-0003-4843-2876, Gröger, D, Sutton, R; https://orcid.org/0000-0002-0188-6005, Venn, N C, Cazzaniga, G, Corral Abascal, L, Tsaur, G, Fechina, L, Emerenciano, M; https://orcid.org/0000-0003-2337-8420, Pombo-de-Oliveira, M S; https://orcid.org/0000-0002-1507-004X, Lund-Aho, T, Lundán, T, Montonen, M, Juvonen, V, Zuna, J; https://orcid.org/0000-0002-0887-3709, Trka, J, Ballerini, P, Lapillonne, H, Van der Velden, V H J; https://orcid.org/0000-0001-9457-3763, Sonneveld, E, Delabesse, E, de Matos, R R C; https://orcid.org/0000-0002-8737-1669, Silva, M L M; https://orcid.org/0000-0003-2549-1320, Bomken, S; https://orcid.org/0000-0001-9163-5738, Katsibardi, K, Keernik, M, Schäfer, Beat W; https://orcid.org/0000-0001-5988-2915, and et al
- Abstract
Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints within the KMT2A gene and the involved translocation partner genes (TPGs) and KMT2A-partial tandem duplications (PTDs) were determined. Including the published data from the literature, a total of 107 in-frame KMT2A gene fusions have been identified so far. Further 16 rearrangements were out-of-frame fusions, 18 patients had no partner gene fused to 5'-KMT2A, two patients had a 5'-KMT2A deletion, and one ETV6::RUNX1 patient had an KMT2A insertion at the breakpoint. The seven most frequent TPGs and PTDs account for more than 90% of all recombinations of the KMT2A, 37 occur recurrently and 63 were identified so far only once. This study provides a comprehensive analysis of the KMT2A recombinome in acute leukemia patients. Besides the scientific gain of information, genomic breakpoint sequences of these patients were used to monitor minimal residual disease (MRD). Thus, this work may be directly translated from the bench to the bedside of patients and meet the clinical needs to improve patient survival.
- Published
- 2023
9. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences
- Author
-
Waanders, E, Scheijen, B, Jongmans, M C J, Venselaar, H, van Reijmersdal, S V, van Dijk, A H A, Pastorczak, A, Weren, R D A, van der Schoot, C E, van de Vorst, M, Sonneveld, E, Hoogerbrugge, N, van der Velden, V H J, Gruhn, B, Hoogerbrugge, P M, van Dongen, J J M, Geurts van Kessel, A, van Leeuwen, F N, and Kuiper, R P
- Published
- 2017
- Full Text
- View/download PDF
10. Human Cell Line Based Assays for Toxic Poly Halogenated and Poly Aromatic Hydrocarbons in Oils and Lipids
- Author
-
van der Burg, B., Jonas, A., Sonneveld, E., and Timmis, Kenneth N., editor
- Published
- 2010
- Full Text
- View/download PDF
11. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia
- Author
-
Marke, R, Havinga, J, Cloos, J, Demkes, M, Poelmans, G, Yuniati, L, van Ingen Schenau, D, Sonneveld, E, Waanders, E, Pieters, R, Kuiper, R P, Hoogerbrugge, P M, Kaspers, G J L, van Leeuwen, F N, and Scheijen, B
- Published
- 2016
- Full Text
- View/download PDF
12. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study
- Author
-
Boer, J M, van der Veer, A, Rizopoulos, D, Fiocco, M, Sonneveld, E, de Groot-Kruseman, H A, Kuiper, R P, Hoogerbrugge, P, Horstmann, M, Zaliova, M, Palmi, C, Trka, J, Fronkova, E, Emerenciano, M, do Socorro Pombo-de-Oliveira, M, Mlynarski, W, Szczepanski, T, Nebral, K, Attarbaschi, A, Venn, N, Sutton, R, Schwab, C J, Enshaei, A, Vora, A, Stanulla, M, Schrappe, M, Cazzaniga, G, Conter, V, Zimmermann, M, Moorman, A V, Pieters, R, and den Boer, M L
- Published
- 2016
- Full Text
- View/download PDF
13. Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse
- Author
-
Antić, Ž., Yu, J., Bornhauser, B.C., Lelieveld, S.H., Ham, C.G. van der, Reijmersdal, S.V. van, Morgado, L., Elitzur, S., Bourquin, J.P., Cazzaniga, G., Eckert, C., Camós, M., Sutton, R., Cavé, H., Moorman, A.V., Sonneveld, E., Geurts van Kessel, A.H.M., Leeuwen, F.N. van, Hoogerbrugge, P.M., Waanders, E., Kuiper, R.P, Antić, Ž., Yu, J., Bornhauser, B.C., Lelieveld, S.H., Ham, C.G. van der, Reijmersdal, S.V. van, Morgado, L., Elitzur, S., Bourquin, J.P., Cazzaniga, G., Eckert, C., Camós, M., Sutton, R., Cavé, H., Moorman, A.V., Sonneveld, E., Geurts van Kessel, A.H.M., Leeuwen, F.N. van, Hoogerbrugge, P.M., Waanders, E., and Kuiper, R.P
- Abstract
Item does not contain fulltext, INTRODUCTION: One-quarter of the relapses in children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occur very early (within 18 months, before completion of treatment), and prognosis in these patients is worse compared to cases that relapse after treatment has ended. METHODS: In this study, we performed a genomic analysis of diagnosis-relapse pairs of 12 children who relapsed very early, followed by a deep-sequencing validation of all identified mutations. In addition, we included one case with a good initial treatment response and on-treatment relapse at the end of upfront therapy. RESULTS: We observed a dynamic clonal evolution in all cases, with relapse almost exclusively originating from a subclone at diagnosis. We identified several driver mutations that may have influenced the outgrowth of a minor clone at diagnosis to become the major clone at relapse. For example, a minimal residual disease (MRD)-based standard-risk patient with ETV6-RUNX1-positive leukemia developed a relapse from a TP53-mutated subclone after loss of the wildtype allele. Furthermore, two patients with TCF3-PBX1-positive leukemia that developed a very early relapse carried E1099K WHSC1 mutations at diagnosis, a hotspot mutation that was recurrently encountered in other very early TCF3-PBX1-positive leukemia relapses as well. In addition to alterations in known relapse drivers, we found two cases with truncating mutations in the cohesin gene RAD21. CONCLUSION: Comprehensive genomic characterization of diagnosis-relapse pairs shows that very early relapses in BCP-ALL frequently arise from minor subclones at diagnosis. A detailed understanding of the therapeutic pressure driving these events may aid the development of improved therapies.
- Published
- 2022
14. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement
- Author
-
Bomken, S, Enshaei, A, Schwalbe, E, Mikulasova, A, Dai, Y, Zaka, M, Fung, K, Bashton, M, Lim, H, Jones, L, Karataraki, N, Winterman, E, Ashby, C, Attarbaschi, A, Bertrand, Y, Bradtke, J, Buldini, B, Burke, G, Cazzaniga, G, Gohring, G, De Groot-Kruseman, H, Haferlach, C, Nigro, L, Parihar, M, Plesa, A, Seaford, E, Sonneveld, E, Strehl, S, Van der Velden, V, Rand, V, Hunger, S, Harrison, C, Bacon, C, Van Delft, F, Loh, M, Moppett, J, Vormoor, J, Walker, B, Moorman, A, Russell, L, Bomken, Simon, Enshaei, Amir, Schwalbe, Edward C, Mikulasova, Aneta, Dai, Yunfeng, Zaka, Masood, Fung, Kent Tm, Bashton, Matthew, Lim, Huezin, Jones, Lisa, Karataraki, Nefeli, Winterman, Emily, Ashby, Cody, Attarbaschi, Andishe, Bertrand, Yves, Bradtke, Jutta, Buldini, Barbara, Burke, G. A. Amos, Cazzaniga, Giovanni, Gohring, Gudrun, De Groot-Kruseman, Hesta A, Haferlach, Claudia, Nigro, Luca Lo, Parihar, Mayur, Plesa, Adriana, Seaford, Emma, Sonneveld, Edwin, Strehl, Sabine, Van der Velden, Vincent Hj, Rand, Vikki, Hunger, Stephen P, Harrison, Christine J, Bacon, Chris M, Van Delft, Frederik W, Loh, Mignon L, Moppett, John, Vormoor, Josef, Walker, Brian A, Moorman, Anthony V, Russell, Lisa J, Bomken, S, Enshaei, A, Schwalbe, E, Mikulasova, A, Dai, Y, Zaka, M, Fung, K, Bashton, M, Lim, H, Jones, L, Karataraki, N, Winterman, E, Ashby, C, Attarbaschi, A, Bertrand, Y, Bradtke, J, Buldini, B, Burke, G, Cazzaniga, G, Gohring, G, De Groot-Kruseman, H, Haferlach, C, Nigro, L, Parihar, M, Plesa, A, Seaford, E, Sonneveld, E, Strehl, S, Van der Velden, V, Rand, V, Hunger, S, Harrison, C, Bacon, C, Van Delft, F, Loh, M, Moppett, J, Vormoor, J, Walker, B, Moorman, A, Russell, L, Bomken, Simon, Enshaei, Amir, Schwalbe, Edward C, Mikulasova, Aneta, Dai, Yunfeng, Zaka, Masood, Fung, Kent Tm, Bashton, Matthew, Lim, Huezin, Jones, Lisa, Karataraki, Nefeli, Winterman, Emily, Ashby, Cody, Attarbaschi, Andishe, Bertrand, Yves, Bradtke, Jutta, Buldini, Barbara, Burke, G. A. Amos, Cazzaniga, Giovanni, Gohring, Gudrun, De Groot-Kruseman, Hesta A, Haferlach, Claudia, Nigro, Luca Lo, Parihar, Mayur, Plesa, Adriana, Seaford, Emma, Sonneveld, Edwin, Strehl, Sabine, Van der Velden, Vincent Hj, Rand, Vikki, Hunger, Stephen P, Harrison, Christine J, Bacon, Chris M, Van Delft, Frederik W, Loh, Mignon L, Moppett, John, Vormoor, Josef, Walker, Brian A, Moorman, Anthony V, and Russell, Lisa J
- Abstract
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) carries an immunoglobulin-MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukaemia and use of unproven individualised treatment schedules. Here we contrast the molecular characteristics of these conditions and investigate historic clinical outcome data. We identified 90 cases registered on a national BCP-ALL clinical trial/registry. Where present, diagnostic material underwent cytogenetic, exome, methylome and transcriptome analysis. Outcome was analysed to define 3-year event free survival (EFS) and overall survival (OS). IG-MYC-r was identified in diverse cytogenetic backgrounds, co-existing with either: established BCP-ALL specific abnormalities (high hyperdiploidy n=3, KMT2A-rearrangement n=6, iAMP21 n=1, BCR-ABL n=1); BCL2/BCL6-rearrangements (n=15); or, most commonly, as the only defining feature (n=64). Within this final group, precursor-like V(D)J breakpoints predominated (8/9) and KRAS mutations were common (5/11). DNA methylation identified a cluster of V(D)J rearranged cases, clearly distinct from Burkitt leukaemia/lymphoma. Children with IG-MYC-r within that subgroup had 3-year EFS of 47% and OS of 60%, representing a high-risk BCP-ALL. To develop effective management strategies this patient group must be allowed access to contemporary, minimal residual disease adapted, prospective clinical trial protocols.
- Published
- 2022
15. Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group
- Author
-
Benetton, M., Merli, P., Walter, C., Hansen, M., Da Ros, A., Polato, K., Tregnago, C., Abrahamsson, J., Strocchio, L., Sonneveld, E., Fogelstrand, L., Von Neuhoff, N., Reinhardt, D., Hasle, H., Pigazzi, M., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Benetton, M., Merli, P., Walter, C., Hansen, M., Da Ros, A., Polato, K., Tregnago, C., Abrahamsson, J., Strocchio, L., Sonneveld, E., Fogelstrand, L., Von Neuhoff, N., Reinhardt, D., Hasle, H., Pigazzi, M., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Hematopoietic stem cell transplantation (HSCT) is a curative post-remission treatment in patients with acute myeloid leukemia (AML), but relapse after transplant is still a challenging event. In recent year, several studies have investigated the molecular minimal residual disease (qPCR-MRD) as a predictor of relapse, but the lack of standardized protocols, cut-offs, and timepoints, especially in the pediatric setting, has prevented its use in several settings, including before HSCT. Here, we propose the first collaborative retrospective I-BFM-AML study assessing qPCR-MRD values in pretransplant bone marrow samples of 112 patients with a diagnosis of AML harboring t(8;21)(q22; q22)RUNX1::RUNX1T1, or inv(16)(p13q22)CBFB::MYH11, or t(9;11)(p21;q23)KMT2A::MLLT3, or FLT3-ITD genetic markers. We calculated an ROC cut-off of 2.1 × 10−4 that revealed significantly increased OS (83.7% versus 57.1%) and EFS (80.2% versus 52.9%) for those patients with lower qPCR-MRD values. Then, we partitioned patients into three qPCR-MRD groups by combining two different thresholds, 2.1 × 10−4 and one lower cut-off of 1 × 10−2, and stratified patients into low-, intermediate-, and high-risk groups. We found that the 5-year OS (83.7%, 68.6%, and 39.2%, respectively) and relapse-free survival (89.2%, 73.9%, and 67.9%, respectively) were significantly different independent of the genetic lesion, conditioning regimen, donor, and stem cell source. These data support the PCR-based approach playing a clinical relevance in AML transplant management.
- Published
- 2022
16. Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome
- Author
-
Oliveira, E, Costa, E, Ciudad, J, Gaipa, G, Sedek, Ł, Barrena, S, Szczepanski, T, Buracchi, C, Silvestri, D, Siqueira, P, Mello, F, Torres, R, Oliveira, L, Fay-Neves, I, Sonneveld, E, van der Velden, V, Mejstrikova, E, Ribera, J, Conter, V, Schrappe, M, van Dongen, J, Land, M, Orfao, A, Oliveira, E, Costa, E, Ciudad, J, Gaipa, G, Sedek, Ł, Barrena, S, Szczepanski, T, Buracchi, C, Silvestri, D, Siqueira, P, Mello, F, Torres, R, Oliveira, L, Fay-Neves, I, Sonneveld, E, van der Velden, V, Mejstrikova, E, Ribera, J, Conter, V, Schrappe, M, van Dongen, J, Land, M, and Orfao, A
- Abstract
For the last two decades, measurable residual disease (MRD) has become one of the most powerful independent prognostic factors in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, the effect of therapy on the bone marrow (BM) microenvironment and its potential relationship with the MRD status and disease free survival (DFS) still remain to be investigated. Here we analyzed the distribution of mesenchymal stem cells (MSC) and endothelial cells (EC) in the BM of treated BCP-ALL patients, and its relationship with the BM MRD status and patient outcome. For this purpose, the BM MRD status and EC/MSC regeneration profile were analyzed by multiparameter flow cytometry (MFC) in 16 control BM (10 children; 6 adults) and 1204 BM samples from 347 children and 100 adult BCP-ALL patients studied at diagnosis (129 children; 100 adults) and follow-up (824 childhood samples; 151 adult samples). Patients were grouped into a discovery cohort (116 pediatric BCP-ALL patients; 338 samples) and two validation cohorts (74 pediatric BCP-ALL, 211 samples; and 74 adult BCP-ALL patients; 134 samples). Stromal cells (i.e., EC and MSC) were detected at relatively low frequencies in all control BM (16/16; 100%) and in most BCP-ALL follow-up samples (874/975; 90%), while they were undetected in BCP-ALL BM at diagnosis. In control BM samples, the overall percentage of EC plus MSC was higher in children than adults (p = 0.011), but with a similar EC/MSC ratio in both groups. According to the MRD status similar frequencies of both types of BM stromal cells were detected in BCP-ALL BM studied at different time points during the follow-up. Univariate analysis (including all relevant prognostic factors together with the percentage of stromal cells) performed in the discovery cohort was used to select covariates for a multivariate Cox regression model for predicting patient DFS. Of note, an increased percentage of EC (>32%) within the BCP-ALL BM stromal cell compartment at day +78 of
- Published
- 2022
17. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern
- Author
-
de Rooij, J D E, Hollink, I H I M, Arentsen-Peters, S T C J M, van Galen, J F, Berna Beverloo, H, Baruchel, A, Trka, J, Reinhardt, D, Sonneveld, E, Zimmermann, M, Alonzo, T A, Pieters, R, Meshinchi, S, van den Heuvel-Eibrink, M M, and Zwaan, C Michel
- Published
- 2013
- Full Text
- View/download PDF
18. Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay
- Author
-
Dekking, E., van der Velden, V.H.J., Böttcher, S., Brüggemann, M., Sonneveld, E., Koning-Goedheer, A., Boeckx, N., Lucio, P., Sedek, L., Szczepański, T., Kalina, T., Kovac, M., Evans, P., Hoogeveen, P.G., Flores-Montero, J., Orfao, A., Comans-Bitter, W.M., Staal, F.J.T., and van Dongen, J.J.M.
- Published
- 2010
- Full Text
- View/download PDF
19. TET2 mutations in childhood leukemia
- Author
-
Langemeijer, S M C, Jansen, J H, Hooijer, J, van Hoogen, P, Stevens-Linders, E, Massop, M, Waanders, E, van Reijmersdal, S V, Stevens-Kroef, M J P L, Zwaan, C M, van den Heuvel-Eibrink, M M, Sonneveld, E, Hoogerbrugge, P M, Geurts van Kessel, A, and Kuiper, R P
- Published
- 2011
- Full Text
- View/download PDF
20. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols
- Author
-
Zuurbier, L, Homminga, I, Calvert, V, Winkel, ML te, Buijs-Gladdines, J G C A M, Kooi, C, Smits, W K, Sonneveld, E, Veerman, A J P, Kamps, W A, Horstmann, M, Petricoin, III, E F, Pieters, R, and Meijerink, J P P
- Published
- 2010
- Full Text
- View/download PDF
21. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL
- Author
-
Kuiper, R P, Waanders, E, van der Velden, V H J, van Reijmersdal, S V, Venkatachalam, R, Scheijen, B, Sonneveld, E, van Dongen, J J M, Veerman, A J P, van Leeuwen, F N, Geurts van Kessel, A, and Hoogerbrugge, P M
- Published
- 2010
- Full Text
- View/download PDF
22. The KMT2Arecombinome of acute leukemias in 2023
- Author
-
Meyer, C., Larghero, P., Almeida Lopes, B., Burmeister, T., Gröger, D., Sutton, R., Venn, N. C., Cazzaniga, G., Corral Abascal, L., Tsaur, G., Fechina, L., Emerenciano, M., Pombo-de-Oliveira, M. S., Lund-Aho, T., Lundán, T., Montonen, M., Juvonen, V., Zuna, J., Trka, J., Ballerini, P., Lapillonne, H., Van der Velden, V. H. J., Sonneveld, E., Delabesse, E., de Matos, R. R. C., Silva, M. L. M., Bomken, S., Katsibardi, K., Keernik, M., Grardel, N., Mason, J., Price, R., Kim, J., Eckert, C., Lo Nigro, L., Bueno, C., Menendez, P., zur Stadt, U., Gameiro, P., Sedék, L., Szczepański, T., Bidet, A., Marcu, V., Shichrur, K., Izraeli, S., Madsen, H. O., Schäfer, B. W., Kubetzko, S., Kim, R., Clappier, E., Trautmann, H., Brüggemann, M., Archer, P., Hancock, J., Alten, J., Möricke, A., Stanulla, M., Lentes, J., Bergmann, A. K., Strehl, S., Köhrer, S., Nebral, K., Dworzak, M. N., Haas, O. A., Arfeuille, C., Caye-Eude, A., Cavé, H., and Marschalek, R.
- Abstract
Chromosomal rearrangements of the human KMT2A/MLLgene are associated with de novoas well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints within the KMT2Agene and the involved translocation partner genes (TPGs) and KMT2A-partial tandem duplications (PTDs) were determined. Including the published data from the literature, a total of 107 in-frame KMT2Agene fusions have been identified so far. Further 16 rearrangements were out-of-frame fusions, 18 patients had no partner gene fused to 5’-KMT2A, two patients had a 5’-KMT2Adeletion, and one ETV6::RUNX1patient had an KMT2Ainsertion at the breakpoint. The seven most frequent TPGs and PTDs account for more than 90% of all recombinations of the KMT2A, 37 occur recurrently and 63 were identified so far only once. This study provides a comprehensive analysis of the KMT2Arecombinome in acute leukemia patients. Besides the scientific gain of information, genomic breakpoint sequences of these patients were used to monitor minimal residual disease (MRD). Thus, this work may be directly translated from the bench to the bedside of patients and meet the clinical needs to improve patient survival.
- Published
- 2023
- Full Text
- View/download PDF
23. Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation
- Author
-
Sciarrillo, R., Wojtuszkiewicz, A., Kooi, I.E., Leon, L.G., Sonneveld, E., Kuiper, R.P., Jansen, G, Giovannetti, E., Kaspers, G.J., Cloos, J., Sciarrillo, R., Wojtuszkiewicz, A., Kooi, I.E., Leon, L.G., Sonneveld, E., Kuiper, R.P., Jansen, G, Giovannetti, E., Kaspers, G.J., and Cloos, J.
- Abstract
Contains fulltext : 220784.pdf (publisher's version ) (Open Access), Glucocorticoid (GC) resistance is a crucial determinant of inferior response to chemotherapy in pediatric acute lymphoblastic leukemia (ALL); however, molecular mechanisms underlying this phenomenon are poorly understood. Deregulated splicing is a common feature of many cancers, which impacts drug response and constitutes an attractive therapeutic target. Therefore, the aim of the current study was to characterize global splicing profiles associated with GC resistance and determine whether splicing modulation could serve as a novel therapeutic option for GC-resistant patients. To this end, 38 primary ALL samples were profiled using RNA-seq-based differential splicing analysis. The impact of splicing modulators was investigated in GC-resistant leukemia cell lines and primary leukemic specimens. Our findings revealed, for the first time, markedly distinct splicing landscapes in ALL samples of B-cell precursor (BCP)-ALL and T-ALL lineages. Differential splicing events associated with GC resistance were involved in RNA processing, a direct response to GCs, survival signaling, apoptosis, cell cycle regulation and energy metabolism. Furthermore, our analyses showed that GC-resistant ALL cell lines and primary samples are sensitive to splicing modulation, alone and in combination with GC. Together, these findings suggest that aberrant splicing is associated with GC resistance and splicing modulators deserve further interest as a novel treatment option for GC-resistant patients.
- Published
- 2020
24. Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting
- Author
-
Hanekamp, D. (Diana), Snel, A.N. (Alexander), Kelder, A. (Angèle), Scholten, W.J. (Willemijn), Khan, N. (Naeem), Metzner, M. (Marlen), Irno-Consalvo, M. (Maria), Sugita, M. (Mayumi), Jong, A.X. (Anja) de, Oude Alink, S. (Sjoerd), Eidhof, H. (Harrie), Wilhelm, M. (Miriam), Feuring-Buske, M. (Michaela), Slomp, J. (Jennichjen), Velden, V.H.J. (Vincent) van der, Sonneveld, E. (Edwin), Guzman, M. (Monica), Roboz, G.J. (Gail J.), Buccisano, F. (Francesco), Vyas, P. (Paresh), Freeman, S. (Sylvie), Bachas, C. (Costa), Ossenkoppele, G.J. (Gert), Schuurhuis, G.J. (Gerrit Jan), Cloos, J. (Jacqueline), Hanekamp, D. (Diana), Snel, A.N. (Alexander), Kelder, A. (Angèle), Scholten, W.J. (Willemijn), Khan, N. (Naeem), Metzner, M. (Marlen), Irno-Consalvo, M. (Maria), Sugita, M. (Mayumi), Jong, A.X. (Anja) de, Oude Alink, S. (Sjoerd), Eidhof, H. (Harrie), Wilhelm, M. (Miriam), Feuring-Buske, M. (Michaela), Slomp, J. (Jennichjen), Velden, V.H.J. (Vincent) van der, Sonneveld, E. (Edwin), Guzman, M. (Monica), Roboz, G.J. (Gail J.), Buccisano, F. (Francesco), Vyas, P. (Paresh), Freeman, S. (Sylvie), Bachas, C. (Costa), Ossenkoppele, G.J. (Gert), Schuurhuis, G.J. (Gerrit Jan), and Cloos, J. (Jacqueline)
- Abstract
Leukaemic stem cells (LSC) have been experimentally defined as the leukaemia-propagating population and are thought to be the cellular reservoir of relapse in acute myeloid leukaemia (AML). Therefore, LSC measurements are warranted to facilitate accurate risk stratification. Previously, we published the composition of a one-tube flow cytometric assay, characterised by the presence of 13 important membrane markers for LSC detection.
- Published
- 2020
- Full Text
- View/download PDF
25. Glucocorticoid resistant pediatric acute lymphoblastic leukemia samples display altered splicing profile and vulnerability to spliceosome modulation
- Author
-
Sciarrillo, R. (Rocco), Wojtuszkiewicz, A. (Anna), Kooi, I.E. (Irsan E.), Leon, L.G. (Leticia), Sonneveld, E. (Edwin), Kuiper, R.P. (Roland), Jansen, G. (Gert), Giovannetti, E. (Elisa), Kaspers, G.J.L. (Gertjan), Cloos, J. (Jacqueline), Sciarrillo, R. (Rocco), Wojtuszkiewicz, A. (Anna), Kooi, I.E. (Irsan E.), Leon, L.G. (Leticia), Sonneveld, E. (Edwin), Kuiper, R.P. (Roland), Jansen, G. (Gert), Giovannetti, E. (Elisa), Kaspers, G.J.L. (Gertjan), and Cloos, J. (Jacqueline)
- Abstract
Glucocorticoid (GC) resistance is a crucial determinant of inferior response to chemotherapy in pediatric acute lymphoblastic leukemia (ALL); however, molecular mechanisms underlying this phenomenon are poorly understood. Deregulated splicing is a common feature of many cancers, which impacts drug response and constitutes an attractive therapeutic target. Therefore, the aim of the current study was to characterize global splicing profiles associated with GC resistance and determine whether splicing modulation could serve as a novel therapeutic option for GC-resistant patients. To this end, 38 primary ALL samples were profiled using RNA-seq-based differential splicing analysis. The impact of splicing modulators was investigated in GC-resistant leukemia cell lines and primary leukemic specimens. Our findings revealed, for the first time, markedly distinct splicing landscapes in ALL samples of B-cell precursor (BCP)-ALL and T-ALL lineages. Differential splicing events associated with GC resistance were involved in RNA processing, a direct response to GCs, survival signaling, apoptosis, cell cycle regulation and energy metabolism. Furthermore, our analyses showed that GC-resistant ALL cell lines and primary samples are sensitive to splicing modulation, alone and in combination with GC. Together, these findings suggest that aberrant splicing is associated with GC resistance and splicing modulators deserve further interest as a novel treatment option for GC-resistant patients.
- Published
- 2020
- Full Text
- View/download PDF
26. Upfront Treatment Influences the Composition of Genetic Alterations in Relapsed Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
- Author
-
Yu, J., Waanders, E., Reijmersdal, S.V. van, Antic, Z., Bosbeek, C.M. van, Sonneveld, E., Groot, H. de, Fiocco, M., Geurts van Kessel, A.H.M., Leeuwen, F.N. van, Pieters, R., Hoogerbrugge, P.M., Kuiper, R.P, Yu, J., Waanders, E., Reijmersdal, S.V. van, Antic, Z., Bosbeek, C.M. van, Sonneveld, E., Groot, H. de, Fiocco, M., Geurts van Kessel, A.H.M., Leeuwen, F.N. van, Pieters, R., Hoogerbrugge, P.M., and Kuiper, R.P
- Abstract
Contains fulltext : 218617.pdf (publisher's version ) (Open Access), Genomic alterations in relapsed B-cell precursor acute lymphoblastic leukemia (BCP-ALL) may provide insight into the role of specific genomic events in relapse development. Along this line, comparisons between the spectrum of alterations in relapses that arise in different upfront treatment protocols may provide valuable information on the association between the tumor genome, protocol components and outcome. Here, we performed a comprehensive characterization of relapsed BCP-ALL cases that developed in the context of 3 completed Dutch upfront studies, ALL8, ALL9, and ALL10. In total, 123 pediatric BCP-ALL relapses and 77 paired samples from primary diagnosis were analyzed for alterations in 22 recurrently affected genes. We found pronounced differences in relapse alterations between the 3 studies. Specifically, CREBBP mutations were observed predominantly in relapses after treatment with ALL8 and ALL10 which, in the latter group, were all detected in medium risk-treated patients. IKZF1 alterations were enriched 2.2-fold (p = 0.01) and 2.9-fold (p < 0.001) in ALL8 and ALL9 relapses compared to diagnosis, respectively, whereas no significant enrichment was found for relapses that were observed after treatment with ALL10. Furthermore, IKZF1 deletions were more frequently preserved from a major clone at diagnosis in relapses after ALL9 compared to relapses after ALL8 and ALL10 (p = 0.03). These data are in line with previous studies showing that the prognostic value of IKZF1 deletions differs between upfront protocols and is particularly strong in the ALL9 regimen. In conclusion, our data reveal a correlation between upfront treatment and the genetic composition of relapsed BCP-ALL.
- Published
- 2020
27. Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation
- Author
-
Sciarrillo, R, Wojtuszkiewicz, A, Kooi, IE, Gonzalez Leon, Leticia, Sonneveld, E, Kuiper, RP (Roland), Jansen, G, Giovannetti, E, Kaspers, GJ, Cloos, J, Sciarrillo, R, Wojtuszkiewicz, A, Kooi, IE, Gonzalez Leon, Leticia, Sonneveld, E, Kuiper, RP (Roland), Jansen, G, Giovannetti, E, Kaspers, GJ, and Cloos, J
- Published
- 2020
28. X-ray mapping in heterocyclic design: VI. X-ray diffraction study of 3-(isonicotinoyl)-2-oxooxazolo[3,2-a]pyridine and the product of its hydrolysis
- Author
-
Rybakov, V. B., Babaev, E. V., Pasichnichenko, K. Yu., and Sonneveld, E. J.
- Published
- 2002
- Full Text
- View/download PDF
29. X-ray mapping in heterocyclic design: IV. Crystal structure determination of 3-(p-nitrobenzoyl)-2-oxooxazolo[3,2-a]pyridine from powder diffraction data
- Author
-
Rybakov, V. B., Zhukov, S. G., Babaev, E. V., and Sonneveld, E. J.
- Published
- 2001
- Full Text
- View/download PDF
30. Study of the reaction of 3,5-diamino-4-carbomethoxypyrazole with acetoacetic ester. Synthesis of pyrazolo[1,5-a]pyrimidine
- Author
-
Makarov, V. A., Solov'eva, N. P., Chernyshev, V. V., Sonneveld, E. J., and Granik, V. G.
- Published
- 2000
- Full Text
- View/download PDF
31. CD73 (5′-nucleotidase) expression has no prognostic value in children with acute lymphoblastic leukemia
- Author
-
Wieten, E, van der Linden-Schrever, B E M, Sonneveld, E, Veerman, A J, and Pieters, R
- Published
- 2011
- Full Text
- View/download PDF
32. Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia
- Author
-
Dekking, E HA, van der Velden, V HJ, Varro, R, Wai, H, Böttcher, S, Kneba, M, Sonneveld, E, Koning, A, Boeckx, N, Van Poecke, N, Lucio, P, Mendonça, A, Sedek, L, Szczepański, T, Kalina, T, Kanderová, V, Hoogeveen, P, Flores-Montero, J, Chillón, M C, Orfao, A, Almeida, J, Evans, P, Cullen, M, Noordijk, A L, Vermeulen, P M, de Man, M T, Dixon, E P, Comans-Bitter, W M, and van Dongen, J JM
- Published
- 2012
- Full Text
- View/download PDF
33. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia
- Author
-
Lhermitte, L., Mejstrikova, E., Sluijs-Gelling, A.J. van der, Grigore, G.E., Sedek, L., Bras, A.E., Gaipa, G., Costa, E.S. da, Novakova, M., Sonneveld, E., Buracchi, C., Bacelar, T.D., Marvelde, J.G.T., Trinquand, A., Asnafi, V., Szczepanski, T., Matarraz, S., Lopez, A., Vidriales, B., Bulsa, J., Hrusak, O., Kalina, T., Lecrevisse, Q., Ayuso, M.M., Bruggemann, M., Verde, J., Fernandez, P., Burgos, L., Paiva, B., Pedreira, C.E., Dongen, J.J.M. van, Orfao, A., Velden, V.H.J. van der, EuroFlow Consortium, Instituto de Salud Carlos III, Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brasil), Ministerio de Sanidad y Consumo (España), Polish Academy of Sciences, Fundações de Amparo à Pesquisa (Brasil), Ministerio de Economía y Competitividad (España), Immunology, Lhermitte, L, Mejstrikova, E, Van Der Sluijs-Gelling, A, Grigore, G, Sedek, L, Bras, A, Gaipa, G, Sobral Da Costa, E, Novakova, M, Sonneveld, E, Buracchi, C, De Sa Bacelar, T, Te Marvelde, J, Trinquand, A, Asnafi, V, Szczepanski, T, Matarraz, S, Lopez, A, Vidriales, B, Bulsa, J, Hrusak, O, Kalina, T, Lecrevisse, Q, Martin Ayuso, M, Bruggemann, M, Verde, J, Fernandez, P, Burgos, L, Paiva, B, Pedreira, C, Van Dongen, J, Orfao, A, and Van Der Velden, V
- Subjects
Adult ,Male ,0301 basic medicine ,Cancer Research ,Myeloid ,Adolescent ,T-cell acute lymphoblastic leukemia (T-ALL) ,Immunophenotyping ,Young Adult ,03 medical and health sciences ,Text mining ,Acute leukemia (AL) ,EuroFlow ,medicine ,Humans ,AL orientation tube (ALOT) ,Child ,Aged ,Aged, 80 and over ,Acute leukemia ,Leukemia ,business.industry ,Orientation (computer vision) ,Infant, Newborn ,Infant ,Myeloid leukemia ,Pattern recognition ,Hematology ,Middle Aged ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Leukemia, Myeloid, Acute ,Statistical classification ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Child, Preschool ,Acute Disease ,B-cell precursor (BCP) ,Female ,Original Article ,Artificial intelligence ,business - Abstract
Precise classification of acute leukemia (AL) is crucial for adequate treatment. EuroFlow has previously designed an AL orientation tube (ALOT) to guide towards the relevant classification panel (T-cell acute lymphoblastic leukemia (T-ALL), B-cell precursor (BCP)-ALL and/or acute myeloid leukemia (AML)) and final diagnosis. Now we built a reference database with 656 typical AL samples (145 T-ALL, 377 BCP-ALL, 134 AML), processed and analyzed via standardized protocols. Using principal component analysis (PCA)-based plots and automated classification algorithms for direct comparison of single-cells from individual patients against the database, another 783 cases were subsequently evaluated. Depending on the database-guided results, patients were categorized as: (i) typical T, B or Myeloid without or; (ii) with a transitional component to another lineage; (iii) atypical; or (iv) mixed-lineage. Using this automated algorithm, in 781/783 cases (99.7%) the right panel was selected, and data comparable to the final WHO-diagnosis was already provided in >93% of cases (85% T-ALL, 97% BCP-ALL, 95% AML and 87% mixed-phenotype AL patients), even without data on the full-characterization panels. Our results show that database-guided analysis facilitates standardized interpretation of ALOT results and allows accurate selection of the relevant classification panels, hence providing a solid basis for designing future WHO AL classifications., The research was performed within the EuroFlow Consortium, which started with an EU-FP6 grant (LSHB-CT-2006-018708) and obtained sustainability by protecting and licensing intellectual property, thereby obtaining royalties, which are exclusively being used for supporting the EuroFlow research program (chairmen: JJMvD and AO). LS, JB and TS were supported by STRATEGMED3/304586/5/NCBR/2017 PersonALL grant of the Polish National Center for Research and Development. ESC acknowledges FAPERJ, Rio de Janeiro, Brazil (E26/110.105/2014; E26/102.191/2013) and Conselho Nacional de Desenvolvimento Científico e Tecnológico—CNPQ of Brazil (400194/2014-7). AO, SM and AL acknowledge the Instituto de Salud Carlos III (MINECO, Madrid, Spain) for the DTS15/00119, and CIBERONC-FEDER-CB16/12/00400 grants. EM, OH, TK and MN were supported by Ministry of Health grant number 15-28525A and NPU LO1604. The research for this manuscript was in part performed within the framework of the Erasmus Postgraduate School Molecular Medicine.
- Published
- 2018
34. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia
- Author
-
Theunissen, P, Mejstrikova, E, Sedek, L, Van Der Sluijs-Gelling, A, Gaipa, G, Bartels, M, Sobral da Costa, E, Kotrova, M, Novakova, M, Sonneveld, E, Buracchi, C, Bonaccorso, P, Oliveira, E, Te Marvelde, J, Szczepanski, T, Lhermitte, L, Hrusak, O, Lecrevisse, Q, Grigore, G, Fronkova, E, Trka, J, Bruggemann, M, Orfao, A, Van Dongen, J, Van Der Velden, V, Theunissen P., Mejstrikova E., Sedek L., Van Der Sluijs-Gelling A. J., Gaipa G., Bartels M., Sobral da Costa E., Kotrova M., Novakova M., Sonneveld E., Buracchi C., Bonaccorso P., Oliveira E., Te Marvelde J. G., Szczepanski T., Lhermitte L., Hrusak O., Lecrevisse Q., Grigore G. E., Fronkova E., Trka J., Bruggemann M., Orfao A., Van Dongen J. J. M., Van Der Velden V. H. J., Theunissen, P, Mejstrikova, E, Sedek, L, Van Der Sluijs-Gelling, A, Gaipa, G, Bartels, M, Sobral da Costa, E, Kotrova, M, Novakova, M, Sonneveld, E, Buracchi, C, Bonaccorso, P, Oliveira, E, Te Marvelde, J, Szczepanski, T, Lhermitte, L, Hrusak, O, Lecrevisse, Q, Grigore, G, Fronkova, E, Trka, J, Bruggemann, M, Orfao, A, Van Dongen, J, Van Der Velden, V, Theunissen P., Mejstrikova E., Sedek L., Van Der Sluijs-Gelling A. J., Gaipa G., Bartels M., Sobral da Costa E., Kotrova M., Novakova M., Sonneveld E., Buracchi C., Bonaccorso P., Oliveira E., Te Marvelde J. G., Szczepanski T., Lhermitte L., Hrusak O., Lecrevisse Q., Grigore G. E., Fronkova E., Trka J., Bruggemann M., Orfao A., Van Dongen J. J. M., and Van Der Velden V. H. J.
- Abstract
A fully-standardized EuroFlow 8–color antibody panel and laboratory procedure was stepwise designed to measure minimal residual disease (MRD) in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with a sensitivity of £1025, comparable to real-time quantitative polymerase chain reaction (RQ-PCR)–based MRD detection via antigen-receptor rearrangements. Leukocyte markers and the corresponding antibodies and fluorochromes were selected based on their contribution in separating BCP-ALL cells from normal/regenerating BCP cells in multidimensional principal component analyses. After 5 multicenter design-test-evaluate-redesign phases with a total of 319 BCP-ALL patients at diagnosis, two 8-color antibody tubes were selected, which allowed separation between normal and malignant BCP cells in 99% of studied patients. These 2 tubes were tested with a new erythrocyte bulk-lysis protocol allowing acquisition of high cell numbers in 377 bone marrow follow-up samples of 178 BCP-ALL patients. Comparison with RQ-PCR–based MRD data showed a clear positive relation between the percentage concordant cases and the number of cells acquired. For those samples with >4 million cells acquired, concordant results were obtained in 93% of samples. Most discordances were clarified upon high-throughput sequencing of antigen-receptor rearrangements and blind multicenter reanalysis of flow cytometric data, resulting in an unprecedented concordance of 98% (97% for samples with MRD < 0.01%). In conclusion, the fully standardized EuroFlow BCP-ALL MRD strategy is applicable in >98% of patients with sensitivities at least similar to RQ-PCR (£1025), if sufficient cells (>4 3 106, preferably more) are evaluated.
- Published
- 2017
35. The European Myeloma Stem Cell Network (MSCNET): B552
- Author
-
Johnsen, H E, Schmitz, A, Fogd, K B, Andersen, H, Vanderkerken, K, Valckenborgh, K, Sonneveld, E V, Duin, M V, Orfao, A, Sanz, R G, Paiva, B, Sahota, S, Pietras, D J, Weston-Bell, N, Babbage, G, Bos, N A, Fuhler, G, Klein, B, Caraux, A, Hose, D, Seckinger, A, Niklas, Z, Pfeifer, S, Schreder, M, Andres, M P, San Miguel, J, Almeida, J, Hoejfeldt, A, Hansen, A L, Dybkaer, K, Bøgsted, M, Urup, T, and Pilgaard, L
- Published
- 2009
36. Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing
- Author
-
Yu, J., Antic, Zeljko, Reijmersdal, S.V. van, Hoischen, A., Sonneveld, E., Waanders, E., Kuiper, R.P., Yu, J., Antic, Zeljko, Reijmersdal, S.V. van, Hoischen, A., Sonneveld, E., Waanders, E., and Kuiper, R.P.
- Abstract
Item does not contain fulltext
- Published
- 2018
37. Pitfalls in short-tandem repeat analysis as quality control for sample mix-up of pediatric acute lymphoblastic leukemia patients
- Author
-
Hoogeveen, P.G. (Patricia), Bie, M. (Maaike) de, Noordijk, R. (Rianne), Sonneveld, E. (Edwin), Koning-Goedheer, A., Beverloo, H.B. (Berna), van de der Velden, V.H.J. (Vincent H.J.), Hoogeveen, P.G. (Patricia), Bie, M. (Maaike) de, Noordijk, R. (Rianne), Sonneveld, E. (Edwin), Koning-Goedheer, A., Beverloo, H.B. (Berna), and van de der Velden, V.H.J. (Vincent H.J.)
- Published
- 2018
- Full Text
- View/download PDF
38. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: A retrospective study by the I-BFM study group
- Author
-
Noort, S., Zimmermann, M., Reinhardt, D., Cuccuini, W., Pigazzi, M., Smith, J., Ries, R. E., Alonzo, T. A., Hirsch, B., Tomizawa, D., Locatelli, Franco, Gruber, T. A., Raimondi, S., Sonneveld, E., Cheuk, D. K., Dworzak, M., Stary, J., Abrahamsson, J., Arad-Cohen, N., Czogala, M., De Moerloose, B., Hasle, H., Meshinchi, S., Van Den Heuvel-Eibrink, M., Michel Zwaan, C., Locatelli F. (ORCID:0000-0002-7976-3654), Noort, S., Zimmermann, M., Reinhardt, D., Cuccuini, W., Pigazzi, M., Smith, J., Ries, R. E., Alonzo, T. A., Hirsch, B., Tomizawa, D., Locatelli, Franco, Gruber, T. A., Raimondi, S., Sonneveld, E., Cheuk, D. K., Dworzak, M., Stary, J., Abrahamsson, J., Arad-Cohen, N., Czogala, M., De Moerloose, B., Hasle, H., Meshinchi, S., Van Den Heuvel-Eibrink, M., Michel Zwaan, C., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
To study the prognostic relevance of rare genetic aberrations in acute myeloid leukemia (AML), such as t(16;21), international collaboration is required. Two different types of t(16;21) translocations can be distinguished: t(16;21)(p11;q22), resulting in the FUS-ERG fusion gene; and t(16;21)(q24;q22), resulting in RUNX1-core binding factor (CBFA2T3). We collected data on clinical and biological characteristics of 54 pediatric AML cases with t(16;21) rearrangements from 14 international collaborative study groups participating in the international Berlin-Frankfurt-Münster (I-BFM) AML study group. The AML-BFM cohort diagnosed between 1997 and 2013 was used as a reference cohort. RUNX1-CBFA2T3 (n 5 23) had significantly lower median white blood cell count (12.5 3 109/L, P 5 .03) compared with the reference cohort. FUS-ERG rearranged AML (n 5 31) had no predominant French-American-British (FAB) type, whereas 76% of RUNX1-CBFA2T3 had an M1/M2 FAB type (M1, M2), significantly different from the reference cohort (P 5 .004). Four-year event-free survival (EFS) of patients with FUS-ERG was 7% (standard error [SE] 5 5%), significantly lower compared with the reference cohort (51%, SE 5 1%, P < .001). Four-year EFS of RUNX1-CBFA2T3 was 77% (SE 5 8%, P 5 .06), significantly higher compared with the reference cohort. Cumulative incidence of relapse was 74% (SE 5 8%) in FUS-ERG, 0% (SE 5 0%) in RUNX1-CBFA2T3, compared with 32% (SE 5 1%) in the reference cohort (P < .001). Multivariate analysis identified both FUS-ERG and RUNX1-CBFA2T3 as independent risk factors with hazard ratios of 1.9 (P < .0001) and 0.3 (P 5 .025), respectively. These results describe 2 clinically relevant distinct subtypes of pediatric AML. Similarly to other core-binding factor AMLs, patients with RUNX1-CBFA2T3 rearranged AML may benefit from stratification in the standard risk treatment, whereas patients with FUS-ERG rearranged AML should be considered high-risk.
- Published
- 2018
39. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia
- Author
-
Lhermitte, L, Mejstrikova, E, Van Der Sluijs-Gelling, A, Grigore, G, Sedek, L, Bras, A, Gaipa, G, Sobral Da Costa, E, Novakova, M, Sonneveld, E, Buracchi, C, De Sa Bacelar, T, Te Marvelde, J, Trinquand, A, Asnafi, V, Szczepanski, T, Matarraz, S, Lopez, A, Vidriales, B, Bulsa, J, Hrusak, O, Kalina, T, Lecrevisse, Q, Martin Ayuso, M, Bruggemann, M, Verde, J, Fernandez, P, Burgos, L, Paiva, B, Pedreira, C, Van Dongen, J, Orfao, A, Van Der Velden, V, Lhermitte, L, Mejstrikova, E, Van Der Sluijs-Gelling, A, Grigore, G, Sedek, L, Bras, A, Gaipa, G, Sobral Da Costa, E, Novakova, M, Sonneveld, E, Buracchi, C, De Sa Bacelar, T, Te Marvelde, J, Trinquand, A, Asnafi, V, Szczepanski, T, Matarraz, S, Lopez, A, Vidriales, B, Bulsa, J, Hrusak, O, Kalina, T, Lecrevisse, Q, Martin Ayuso, M, Bruggemann, M, Verde, J, Fernandez, P, Burgos, L, Paiva, B, Pedreira, C, Van Dongen, J, Orfao, A, and Van Der Velden, V
- Abstract
Precise classification of acute leukemia (AL) is crucial for adequate treatment. EuroFlow has previously designed an AL orientation tube (ALOT) to guide towards the relevant classification panel (T-cell acute lymphoblastic leukemia (T-ALL), B-cell precursor (BCP)-ALL and/or acute myeloid leukemia (AML)) and final diagnosis. Now we built a reference database with 656 typical AL samples (145 T-ALL, 377 BCP-ALL, 134 AML), processed and analyzed via standardized protocols. Using principal component analysis (PCA)-based plots and automated classification algorithms for direct comparison of single-cells from individual patients against the database, another 783 cases were subsequently evaluated. Depending on the database-guided results, patients were categorized as: (i) typical T, B or Myeloid without or; (ii) with a transitional component to another lineage; (iii) atypical; or (iv) mixed-lineage. Using this automated algorithm, in 781/783 cases (99.7%) the right panel was selected, and data comparable to the final WHO-diagnosis was already provided in >93% of cases (85% T-ALL, 97% BCP-ALL, 95% AML and 87% mixed-phenotype AL patients), even without data on the full-characterization panels. Our results show that database-guided analysis facilitates standardized interpretation of ALOT results and allows accurate selection of the relevant classification panels, hence providing a solid basis for designing future WHO AL classifications.
- Published
- 2018
40. Pitfalls in short-tandem repeat analysis as quality control for sample mix-up of pediatric acute lymphoblastic leukemia patients
- Author
-
Hoogeveen, Patricia, de Bie, Maaike, Noordijk, Rianne, Sonneveld, E, Koning-Goedheer, A, Beverloo, HB, van der Velden, Vincent, Hoogeveen, Patricia, de Bie, Maaike, Noordijk, Rianne, Sonneveld, E, Koning-Goedheer, A, Beverloo, HB, and van der Velden, Vincent
- Published
- 2018
41. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients
- Author
-
Scheijen, B., Boer, J.M.A., Marke, R., Tijchon, E.J., Ingen Schenau, D.S. van, Waanders, E., Emst, L. van, Meer, L.T. van der, Pieters, R., Escherich, G., Horstmann, M.A., Sonneveld, E., Venn, N., Sutton, R., Dalla-Pozza, L., Kuiper, R.P., Hoogerbrugge, P.M., Boer, M.L. Den, Leeuwen, F.N. van, Scheijen, B., Boer, J.M.A., Marke, R., Tijchon, E.J., Ingen Schenau, D.S. van, Waanders, E., Emst, L. van, Meer, L.T. van der, Pieters, R., Escherich, G., Horstmann, M.A., Sonneveld, E., Venn, N., Sutton, R., Dalla-Pozza, L., Kuiper, R.P., Hoogerbrugge, P.M., Boer, M.L. Den, and Leeuwen, F.N. van
- Abstract
Contains fulltext : 169866.pdf (publisher's version ) (Open Access), Deletions and mutations affecting lymphoid transcription factor IKZF1 (IKAROS) are associated with an increased relapse risk and poor outcome in B-cell precursor acute lymphoblastic leukemia. However, additional genetic events may either enhance or negate the effects of IKZF1 deletions on prognosis. In a large discovery cohort of 533 childhood B-cell precursor acute lymphoblastic leukemia patients, we observed that single-copy losses of BTG1 were significantly enriched in IKZF1-deleted B-cell precursor acute lymphoblastic leukemia (P=0.007). While BTG1 deletions alone had no impact on prognosis, the combined presence of BTG1 and IKZF1 deletions was associated with a significantly lower 5-year event-free survival (P=0.0003) and a higher 5-year cumulative incidence of relapse (P=0.005), when compared with IKZF1-deleted cases without BTG1 aberrations. In contrast, other copy number losses commonly observed in B-cell precursor acute lymphoblastic leukemia, such as CDKN2A/B, PAX5, EBF1 or RB1, did not affect the outcome of IKZF1-deleted acute lymphoblastic leukemia patients. To establish whether the combined loss of IKZF1 and BTG1 function cooperate in leukemogenesis, Btg1-deficient mice were crossed onto an Ikzf1 heterozygous background. We observed that loss of Btg1 increased the tumor incidence of Ikzf1+/- mice in a dose-dependent manner. Moreover, murine B cells deficient for Btg1 and Ikzf1+/- displayed increased resistance to glucocorticoids, but not to other chemotherapeutic drugs. Together, our results identify BTG1 as a tumor suppressor in leukemia that, when deleted, strongly enhances the risk of relapse in IKZF1-deleted B-cell precursor acute lymphoblastic leukemia, and augments the glucocorticoid resistance phenotype mediated by the loss of IKZF1 function.
- Published
- 2017
42. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences
- Author
-
Waanders, E., Scheijen, B., Jongmans, M.C.J., Venselaar, H., Reijmersdal, S.V. van, Dijk, A.H.A. van, Pastorczak, A., Weren, R.D.A., Schoot, C.E. van der, Vorst, J.M. van de, Sonneveld, E., Hoogerbrugge, N., Velden, V.H. van der, Gruhn, B., Hoogerbrugge, P.M., Dongen, J.J. van, Geurts van Kessel, A.H.M., Leeuwen, F.N. van, Kuiper, R.P., Waanders, E., Scheijen, B., Jongmans, M.C.J., Venselaar, H., Reijmersdal, S.V. van, Dijk, A.H.A. van, Pastorczak, A., Weren, R.D.A., Schoot, C.E. van der, Vorst, J.M. van de, Sonneveld, E., Hoogerbrugge, N., Velden, V.H. van der, Gruhn, B., Hoogerbrugge, P.M., Dongen, J.J. van, Geurts van Kessel, A.H.M., Leeuwen, F.N. van, and Kuiper, R.P.
- Abstract
Contains fulltext : 170242.pdf (publisher's version ) (Closed access)
- Published
- 2017
43. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia
- Author
-
Theunissen, Prisca, Mejstrikova, E, Sedek, L, van der Sluijs-Gelling, AJ, Gaipa, G, Bartels, M, Costa, ES, Kotrova, M, Novakova, M, Sonneveld, E, Buracchi, C, Bonaccorso, P, Oliveira, E, te Marvelde, Jeroen, Szczepanski, T, Lhermitte, L, Hrusak, O, Lecrevisse, Q, Grigore, GE, Fronkova, E, Trka, J, Bruggemann, M, Orfao, A, Dongen, Jacques, van der Velden, Vincent, Theunissen, Prisca, Mejstrikova, E, Sedek, L, van der Sluijs-Gelling, AJ, Gaipa, G, Bartels, M, Costa, ES, Kotrova, M, Novakova, M, Sonneveld, E, Buracchi, C, Bonaccorso, P, Oliveira, E, te Marvelde, Jeroen, Szczepanski, T, Lhermitte, L, Hrusak, O, Lecrevisse, Q, Grigore, GE, Fronkova, E, Trka, J, Bruggemann, M, Orfao, A, Dongen, Jacques, and van der Velden, Vincent
- Published
- 2017
44. Recurrent Translocation t(10;17)(p15;q21) in Minimally Differentiated Acute Myeloid Leukemia Results in ZMYND11/MBTD1 Fusion
- Author
-
Rooij, J.D.E. de, Heuvel-Eibrink, M.M. van den, Kollen, W.J.W., Sonneveld, E., Kaspers, G.J.L., Beverloo, H.B., Fornerod, M., Pieters, R., and Zwaan, C.M.
- Published
- 2016
45. Standardized Next-Generation Flow Cytometry for Highly Sensitive Mrd Measurements in B-Cell Acute Lymphoblastic Leukemia
- Author
-
Theunissen, Prisca, Mejstrikova, E, Sedek, L, van der Sluijs, A, Gaipa, G, Bartels, M, Sobral de Costa, E, Kotrova, M, Novakova, M, Sonneveld, E, Baracchi, C, Bonaccorso, P, Oliviera, E, te Marvelde, Jeroen, Szczepanski, Tomek, Lhermitte, L, Hrusak, O, Lecrevisse, Q, Grigore, GE, Fronkova, E, Trka, J, Bruggemann, M, Orfao, A, Dongen, Jacques, van der Velden, Vincent, van Dongen, JJM, Immunology, and Plastic and Reconstructive Surgery and Hand Surgery
- Published
- 2016
46. Recurrent Translocation t(10;17)(p15;q21) in Minimally Differentiated Acute Myeloid Leukemia Results in ZMYND11/MBTD1 Fusion
- Author
-
de Rooij -, Jasmijn, Van den Heuvel - Eibrink, Marry, Kollen, WJW, Sonneveld, E, Kaspers, GJL, Beverloo, Berna, Fornerod, M.W.J., Pieters, R, Zwaan, C.M., Pediatrics, and Clinical Genetics
- Published
- 2016
47. MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML
- Author
-
Larmonie, N S D, primary, Arentsen-Peters, T C J M, additional, Obulkasim, A, additional, Valerio, D, additional, Sonneveld, E, additional, Danen-van Oorschot, A A, additional, de Haas, V, additional, Reinhardt, D, additional, Zimmermann, M, additional, Trka, J, additional, Baruchel, A, additional, Pieters, R, additional, van den Heuvel-Eibrink, M M, additional, Zwaan, C M, additional, and Fornerod, M, additional
- Published
- 2017
- Full Text
- View/download PDF
48. Glucocorticoid mediated expression of dioxin target genes in rat H4IIe cells but not in human HepG2 and T47D cells
- Author
-
Sonneveld, E., Jansen, H.J.., Man, S., Jonas, A.J.G., Brouwer, A., van der Burg, B., Chemistry and Biology, and Institute for Environmental Studies
- Published
- 2006
49. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia
- Author
-
Marke, R., Havinga, J., Cloos, J., Demkes, M., Poelmans, G., Yuniati, L., Ingen Schenau, D.S. van, Sonneveld, E., Waanders, E., Pieters, R., Kuiper, R.P., Hoogerbrugge, P.M., Kaspers, G.J., Leeuwen, F.N. van, Scheijen, B., Marke, R., Havinga, J., Cloos, J., Demkes, M., Poelmans, G., Yuniati, L., Ingen Schenau, D.S. van, Sonneveld, E., Waanders, E., Pieters, R., Kuiper, R.P., Hoogerbrugge, P.M., Kaspers, G.J., Leeuwen, F.N. van, and Scheijen, B.
- Abstract
Item does not contain fulltext
- Published
- 2016
50. MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia
- Author
-
Verboon, P. (Peter), Obulkasim, A. (Askar), Rooij, J.D. (Johan) de, Katsman-Kuipers, J.E. (Jenny), Sonneveld, E. (Edwin), Baruchel, A. (André), Trka, J. (Jan), Reinhardt, D. (Dirk), Pieters, R. (Rob), Cloos, J. (Jacqueline), Kaspers, G.J.L. (Gertjan), Klusmann, J.-H., Zwaan, C.M. (Michel), Fornerod, M.W.J. (Maarten), Heuvel-Eibrink, M.M. (Marry) van den, Verboon, P. (Peter), Obulkasim, A. (Askar), Rooij, J.D. (Johan) de, Katsman-Kuipers, J.E. (Jenny), Sonneveld, E. (Edwin), Baruchel, A. (André), Trka, J. (Jan), Reinhardt, D. (Dirk), Pieters, R. (Rob), Cloos, J. (Jacqueline), Kaspers, G.J.L. (Gertjan), Klusmann, J.-H., Zwaan, C.M. (Michel), Fornerod, M.W.J. (Maarten), and Heuvel-Eibrink, M.M. (Marry) van den
- Abstract
The most important reason for therapy failure in pediatric acute myeloid leukemia (AML) is relapse. In order to identify miRNAs that contribute to the clonal evolution towards relapse in pediatric AML, miRNA expression profiling of 127 de novo pediatric AML cases were used. In the diagnostic phase, no miRNA signatures could be identified that were predictive for relapse occurrence, in a large pediatric cohort, nor in a nested mixed lineage leukemia (MLL)-rearranged pediatric cohort. AML with MLL- rearrangements are found in 15-20% of all pediatric AML samples, and reveal a relapse rate up to 50% for certain translocation partner subgroups. Therefore, microRNA expression profiling of six paired initial diagnosis-relapse MLL-rearranged pediatric AML samples (test cohort) and additional eight paired initial diagnosisrelapse samples with MLL-rearrangements (validation cohort) was performed. A list of 53 differentially expressed miRNAs was identified of which the miR-106b~25 cluster, located in intron 13 of MCM7, was the most prominent. These differentially expressed miRNAs however could not predict a relapse in de novo AML samples with MLLrearrangements at diagnosis. Furthermore, higher mRNA expression of both MCM7 and its upstream regulator E2F1 was found in relapse samples with MLL-rearrangements. In conclusion, we identified the miR-106b~25 cluster to be upregulated in relapse pediatric AML with MLL-rearrangements.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.